中国临床保健杂志
中國臨床保健雜誌
중국림상보건잡지
CHINESE JOURNAL OF CLINICAL HEALTHCARE
2015年
3期
290-293
,共4页
柳长青%徐汉杰%周颖%赵卫东
柳長青%徐漢傑%週穎%趙衛東
류장청%서한걸%주영%조위동
卵巢肿瘤%抗药性,肿瘤%顺铂%紫杉酚%氟尿嘧啶
卵巢腫瘤%抗藥性,腫瘤%順鉑%紫杉酚%氟尿嘧啶
란소종류%항약성,종류%순박%자삼분%불뇨밀정
Ovarian neoplasms%Drug resistance,neoplasm%Cisplatin%Paclitaxel%Fluorouracil
目的探讨 miR-199在卵巢癌细胞株中的表达,寻找卵巢癌化疗敏感性的指标。方法组学分析找出在顺铂敏感性不同的卵巢癌细胞株,miR-199的表达量差异较为显著,qRT-PCR 和 western blot 方法检测瞬时转染 miR199 mimic /antagomir 后的卵巢癌细胞株,P63表达水平发生显著变化。结果miR-199在对顺铂耐药的 ES-2细胞中表达水平高于在对顺铂耐药的 SKOV3细胞中的表达,miR-199的下游蛋白 P63的表达也有差异。结论miR-199与 P63在一定程度上可以预测卵巢癌顺铂化疗敏感性,miR-199可能是通过其下游靶基因 P63发挥其在卵巢癌顺铂化疗敏感性中的作用。
目的探討 miR-199在卵巢癌細胞株中的錶達,尋找卵巢癌化療敏感性的指標。方法組學分析找齣在順鉑敏感性不同的卵巢癌細胞株,miR-199的錶達量差異較為顯著,qRT-PCR 和 western blot 方法檢測瞬時轉染 miR199 mimic /antagomir 後的卵巢癌細胞株,P63錶達水平髮生顯著變化。結果miR-199在對順鉑耐藥的 ES-2細胞中錶達水平高于在對順鉑耐藥的 SKOV3細胞中的錶達,miR-199的下遊蛋白 P63的錶達也有差異。結論miR-199與 P63在一定程度上可以預測卵巢癌順鉑化療敏感性,miR-199可能是通過其下遊靶基因 P63髮揮其在卵巢癌順鉑化療敏感性中的作用。
목적탐토 miR-199재란소암세포주중적표체,심조란소암화료민감성적지표。방법조학분석조출재순박민감성불동적란소암세포주,miR-199적표체량차이교위현저,qRT-PCR 화 western blot 방법검측순시전염 miR199 mimic /antagomir 후적란소암세포주,P63표체수평발생현저변화。결과miR-199재대순박내약적 ES-2세포중표체수평고우재대순박내약적 SKOV3세포중적표체,miR-199적하유단백 P63적표체야유차이。결론miR-199여 P63재일정정도상가이예측란소암순박화료민감성,miR-199가능시통과기하유파기인 P63발휘기재란소암순박화료민감성중적작용。
Objective In this study,we aimed to detect the expression of miR -199 and searched for chemo-therapy sensitivity of indicators in ovarian cancer cell lines and.Methods Omics analysis had found that in ovarian cancer cell lines which had different sensitivities to cisplatin,the difference of expression of miR -199 is significant. Then used specificity methylation PCR and western blot to verify the expression level of P63 gene in ovarian cancer cell lines of the transient transfection miR199 mimic /antagomir.Results The expression level of miR-199 in ES-2 is much higher than in the expression of SKOV3 cells.The expression of p63 is negatively correlated with the expression of miR-199.Conclusions miR-199 and P63 may predict the sensitivity to cisplatin chemotherapy to some extent. miR-199 may effect the sensitivity to cisplatin chemotherapy of ovarian cancer by regulating its downstream target genes P63.